华润医药(03320.HK)旗下喷他佐辛注射液获得药品补充申请批准通知书

阿斯达克财经
31 Dec 2024

华润医药(03320.HK) 公布,旗下华润双鹤药业收到国家药监局颁发的喷他佐辛注射液《药品补充申请批准通知书》,并视同通过一致性评价。

公司指,喷他佐辛注射液适用于各种慢性剧痛,如癌性疼痛、创伤性疼痛、手术后疼痛,也可用于手术前或麻醉前给药,作为外科手术麻醉的辅助用药。根据国家药监局信息显示,中国境内已批准上市的喷他佐辛注射液生产企业共3家,均通过或视同通过一致性评价。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-30 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10